You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 114 No. 5, May 1978 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Psoralen-UVA-Treated Psoriatic Lesions

Ultrastructural Changes

Ken Hashimoto, MD; Hiromu Kohda, MD, PhD; Masanobu Kumakiri, MD; Steven L. Blender, MD; Isaac Willis, MD

Arch Dermatol. 1978;114(5):711-722.


Abstract

• Psoralen-ultraviolet light (PUVA)-treated psoriatic lesions were studied for ultrastructural changes. In early stages of treatment, sunburn cells in the epidermis and bizarre giant cells in the dermis were more frequently observed. When clinical improvement was apparent, these changes had subsided. Dermal abnormality in long-term therapy consisted of a thick perivascular coat of amorphous substance. No abnormality was found in the epidermal keratinocytes in long-term therapy, except a clustering and giant cell formation of melanocytes, a heavy melanization of keratinocytes, and hyperkeratosis. Low-dose initiation and slow increment of both 8-methoxypsoralen and UVA is probably a reasonable regimen for benign dermatoses such as psoriasis because it will allow enough time for the skin to become more protected, while the therapeutic results are as satisfactory as in a high-dose schedule.

(Arch Dermatol 114:711-722, 1978)



Author Affiliations

From the Veterans Administration Hospital and the Division of Dermatology, Department of Medicine, University of Tennessee Center for the Health Sciences, Memphis (Drs Hashimoto, Kohda, Kumakiri, and Blender); and the Division of Dermatology, Department of Medicine, Veterans Administration Hospital, Decataur, Ga (Dr Willis).


Footnotes

Accepted for publication Aug 30, 1977.

Reprint requests to Research Service (151), Veterans Administration Center, 4100 W Third St, Dayton, OH 45428 (Dr Hashimoto).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Long-term Risks of Psoralen and UV-A Therapy for Psoriasis
Farber et al.
Arch Dermatol 1983;119:426-431.
ABSTRACT  

Acquired Linear Dermal Melanocytosis: Nerve Course Distribution
Pariser and Bluemink
Arch Dermatol 1982;118:125-128.
ABSTRACT  

Amyloid Deposition After Psoriasis Therapy With Psoralen and Long-Wave Ultraviolet Light
Greene and Cox
Arch Dermatol 1979;115:1200-1202.
ABSTRACT  

Epidermal Dystrophy: Occurrence After Psoriasis Therapy With Psoralen and Long-wave Ultraviolet Light
Cox and Abel
Arch Dermatol 1979;115:567-570.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1978 American Medical Association. All Rights Reserved.